An Act to amend 961.385 (2) (cs) 1., 961.385 (5) (b) and 961.385 (6) (a) of the statutes; Relating to: the prescription drug monitoring program. (FE)
Impact
By extending the review requirements for practitioners, AB68 reinforces the state's initiative to promote safe prescribing practices and enhance patient safety. The expectation is that by continuing to mandate record reviews, healthcare providers will have better access to patient drug histories, which can help prevent potential misuse and assist in making informed prescribing decisions. Consequently, this bill could have significant implications for healthcare providers, pharmacies, and patients throughout Wisconsin.
Summary
Assembly Bill 68 focuses on the modification of the prescription drug monitoring program (PDMP) in Wisconsin. The bill aims to prolong specific provisions concerning the review of patient records prior to prescribing controlled substances. Initially, the requirement to review records was set to expire on April 1, 2025; however, AB68 proposes to extend this expiration date to April 1, 2030. This extension signifies a commitment to ongoing monitoring and oversight of prescription medications, particularly in the context of the ongoing challenges posed by opioid misuse and other substance abuses.
Contention
Although the bill appears to have widespread support due to its focus on improving healthcare outcomes, discussions around the bill may involve varying perspectives on the extent of regulation needed in the healthcare sector. Some stakeholders might argue that the extended requirements could place additional burdens on healthcare providers, complicating the prescribing process. In contrast, advocates for the bill emphasize the necessity of rigorous monitoring to combat the ongoing opioid crisis and ensure that patients receive appropriate care.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.